Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic.
about
Virotherapy: cancer gene therapy at last?RNA therapeutics: RNAi and antisense mechanisms and clinical applicationsGold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia.Nucleic Acid Bioconjugates in Cancer Detection and Therapy.Strategies to Inhibit Myc and Their Clinical ApplicabilityAnti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapyNovel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.Inhibition of EGF Uptake by Nephrotoxic Antisense Drugs In Vitro and Implications for Preclinical Safety Profiling.Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics.Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance.New Modalities for Challenging Targets in Drug Discovery.Functionalized chitosan derivatives as nonviral vectors: physicochemical properties of acylated N,N,N-trimethyl chitosan/oligonucleotide nanopolyplexes.Enhancing the pharmacokinetic/pharmacodynamic properties of therapeutic nucleotides using lipid nanoparticle systems.Mucin-mediated nanocarrier disassembly for triggered uptake of oligonucleotides as a delivery strategy for the potential treatment of mucosal tumours.Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates.Oligonucleotide-targeting periostin ameliorates pulmonary fibrosis.Long Noncoding RNA in Cancer: Wiring Signaling Circuitry.Versatile Method for the Site-Specific Modification of DNA with Boron Clusters: Anti-Epidermal Growth Factor Receptor (EGFR) Antisense Oligonucleotide Case.miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases.The potential of antisense oligonucleotide therapies for inherited childhood lung diseases.A Dominant Negative Antisense Approach Targeting β-Catenin.Hydrogel-Assisted Antisense LNA Gapmer Delivery for In Situ Gene Silencing in Spinal Cord Injury.RNA Therapeutics in Cardiovascular Precision MedicineOligonucleotides Targeting Telomeres and Telomerase in CancerOligonucleotides containing a piperazino-modified 2′-amino-LNA monomer exhibit very high duplex stability and remarkable nuclease resistance
P2860
Q28066228-D38F0D84-CAE3-48BA-8BA3-3AD50D73C19AQ28829240-37022B16-C1A2-40C7-916E-2C692337B2D8Q33701925-3CF0D9BE-986F-4747-97E3-FCAD84073FCDQ35867875-59288FAB-6DB6-402C-8A5D-C1CB4095FE71Q36303678-20B6B71D-8956-4B11-8ECA-4C3C87089AC7Q37301832-B8268CEF-8903-4208-A501-7E70CEBD4162Q37370563-45A97F17-EF23-42CF-B070-84C8B3B62E36Q37718074-1B3BE0F2-D694-4559-A9D3-DB45659F41B0Q37718173-1CDB3A7C-71EE-46AE-B0E5-ECFE87D9CFF7Q38286217-C902EF2D-0B92-4836-9E41-D8030CECC5FFQ38289100-61F16A88-0F61-427C-99E1-123465C23CB0Q38296661-765CA9A9-BFFC-490B-986A-19215ADEBCECQ38591825-6D43DD65-A5FF-416E-904F-EA20CD1E2606Q38809725-368BA21B-AD5E-4B12-A72B-DE69DB7C8F46Q39667223-DCA676F6-60AF-410F-B27F-F4280E5258EBQ45870950-D705F688-D7D3-4853-8726-34337544195DQ47258279-E7CA70E6-0074-4863-93AB-8E584881D1BDQ47651762-FDC8E9F9-851C-4C16-8213-54A91A7E9090Q47699115-45537BFB-0372-4956-9143-22D5AF41F260Q50146324-E14E59B8-2528-404D-8313-95F8925EECE0Q55075922-EC1EF2A3-010A-4A3A-8C77-B86A2381AA23Q55398328-0F29FCDC-EA69-4CDF-AC62-4CF78C1AF1B1Q57174720-44B96E61-B920-43AD-B6F3-859DC9892463Q58696640-6DA9181E-F88E-44C9-850C-157699B8493FQ59003688-8ADC535D-5E27-4035-A864-84A55029CCB3
P2860
Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic.
@en
type
label
Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic.
@en
prefLabel
Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic.
@en
P2860
P356
P1476
Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic.
@en
P2093
Pedro M D Moreno
P2860
P356
10.3389/FCHEM.2014.00087
P577
2014-10-14T00:00:00Z